14
2023-04
Suzhou, April 14, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the first patient enrollment in Phase II clinical trial of its in-house developed first-in-class proteolysis targeting chimera (PROTAC) compound GT20029 in China for the treatment of male androgenetic alopecia (AGA). GT20029 is the world’s first topical PROTAC compound which entered the Phase II clinical stage.
30
2023-03
Kintor Pharma Announces 2022 Annual Results and Recent Business Progress
Suzhou, March 30, 2023 - Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022.
28
2023-03
Suzhou, March 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults.
21
2023-03
The 2023 Annual Meeting of American Academy of Dermatology Association (AAD 2023) was held from 17 to 21 March 2023 in New Orleans, Louisiana, United States. As one of the largest, most influential and representative of all dermatologic associations, dermatologists from around the world shared the latest research advances in the field of dermatology. Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939)’s self-developed and potential first-in-class topical drug candidates pyrilutamide (KX-826) and GT20029 have attracted a lot of attention at the meeting, demonstrating the company's innovative capabilities and the therapeutic potential of its androgenetic alopecia (AGA) and acne pipelines.
16
2023-03
Kintor Pharma Announces Preclinical Data of GT1708F at AACR 2023
Suzhou, March 16, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the latest preclinical data from the company’s hedgehog inhibitor GT1708F for the treatment of Acute Myeloid Leukemia (AML) has been selected for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting, and the abstract is available on AACR’s official website.
10
2023-02
Suzhou, February 10, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound. The data showed GT20029 was safe, well tolerated and had good pharmacokinetic characteristics in healthy subjects as well as subjects with androgenetic alopecia (AGA) or acne. GT20029 is the first topical PROTAC compound in the world which has completed Phase I clinical trial in both China and the U.S..
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn